Drug

Itacitinib

Status:
Phase 2
Condition:
Lung Transplant
Intervention Type:
Oral Drug
Funder Type:
Industry

Drug Details

Itacitinib is a novel and selective JAK1 inhibitor.

Study Purpose

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).

Find a Clinical Trial